Breaking News

Monrol to Establish a Legal Entity and Manufacturing Facility in Germany

The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy.

Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany.
 
The new facility will focus on the manufacture of SPECT products and radiopharmaceutical products for radioligand therapy such as Gallium-68 generator and n.c.a Lutetium-177. Developed by Monrol R&D teams, these products are widely used in the production of radiopharmaceuticals for cancer patients. The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services.
 
Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations. The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros ($29.4 million).

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters